Sandoz Group AG (SDZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sandoz Group AG (SDZ) has a cash flow conversion efficiency ratio of 0.059x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF523.00 Million) by net assets (CHF8.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sandoz Group AG - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Sandoz Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sandoz Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sandoz Group AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Merchants Bank Co. Ltd
F:M4B
|
0.030x |
|
Transurban Group
AU:TCL
|
0.124x |
|
KC40
F:KC40
|
0.090x |
|
Ralph Lauren Corp. Cl A
LSE:0KTS
|
0.270x |
|
Bharat Electronics Limited
NSE:BEL_old
|
0.013x |
|
Expedia Group Inc.
NASDAQ:EXPE
|
-0.192x |
|
Tenaris S.A.
SA:T1SS34
|
0.106x |
|
China Construction Bank Co
SHG:601939
|
0.155x |
Annual Cash Flow Conversion Efficiency for Sandoz Group AG (2020–2024)
The table below shows the annual cash flow conversion efficiency of Sandoz Group AG from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF8.16 Billion | CHF656.00 Million | 0.080x | +113.76% |
| 2023-12-31 | CHF8.65 Billion | CHF325.31 Million | 0.038x | -100.00% |
| 2022-12-31 | CHF77.14K | CHF1.17 Billion | 15142.076x | +9097643.39% |
| 2021-12-31 | CHF7.44 Billion | CHF1.24 Billion | 0.166x | +10.25% |
| 2020-12-31 | CHF6.83 Billion | CHF1.03 Billion | 0.151x | -- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage f… Read more